Researchers at the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine have identified IL1RAP as a potential weak point in the inflammatory network that shields pancreatic tumors from treatment. Published in JCI Insight, this breakthrough aims to dismantle the tumor’s fibrous microenvironment, paving the way for an innovative clinical trial combining targeted drug therapy with chemoimmunotherapy before surgery.
The Dense Armor of Pancreatic Malignancies
Pancreatic cancer remains notoriously difficult to treat. Unlike other malignancies, these tumors do not consist solely of mutated cells. Instead, they are encased in a dense, fibrous microenvironment made of scar-like tissue, supporting cells, and immune components. This barrier restricts drug penetration, blunts immune responses, and helps cancer cells survive under stress.
When chemotherapy damages cancer cells, the surrounding cellular network frequently helps the disease adapt and recover. While recent progress with KRAS-targeted drugs has extended survival for patients with metastatic disease, bringing similar clinical wins to patients with operable tumors has remained elusive. This dynamic has driven an urgent medical need for novel strategies that can be deployed in the preoperative setting.
Targeting the Central Signaling Hub
Led by Jashodeep Datta, M.D., a pancreatic and hepatobiliary surgical oncologist and co-leader of the Gastrointestinal Site Disease Group at Sylvester, researchers zeroed in on IL1RAP. This receptor plays a critical role in transmitting inflammatory signals across the cellular network.
“When we target IL1RAP, we are blocking a shared ‘helper’ receptor that many inflammatory signals rely on to transmit their message,” Datta explained regarding the mechanism.
Disrupting the Inflamed Microenvironment
IL1RAP functions as a vital link connecting cancer cells, immune cells, and fibroblasts—the cells responsible for generating structural tumor tissue. Because the receptor acts as a shared control point for multiple pathways, blocking it disrupts a wide network simultaneously. This intervention addresses the “inflamed but immune-suppressed” state typical of pancreatic tumors, where inflammatory signals run high while disease-fighting T cells remain restrained.
Preclinical experiments showed that inhibiting IL1RAP fundamentally alters the tumor microenvironment. Following treatment, immune-suppressive cells declined in number, T-cell activity increased, and fibrosis decreased. Consequently, the tumors demonstrated heightened vulnerability to combination therapies.
Translational Research Reaches the Clinic
These findings have directly shaped an upcoming clinical trial at Sylvester. The first-of-its-kind neoadjuvant study will evaluate an IL1RAP-targeted drug paired with chemoimmunotherapy in patients with operable pancreatic cancer prior to surgical removal.
“Moving this work into a clinical trial is a landmark development for our GI cancer program at Sylvester,” Datta noted, emphasizing the translational nature of the research. Because patients receive the intervention prior to surgery, medical teams will be able to analyze tissue samples directly to measure how effectively the targeted therapy breaks down the tumor’s defenses.
